Clinical trials: active, in Armenia
Geographic Atrophy of the Macula
A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD
Age-related macular degeneration (AMD) affects millions of elderly patients. When advanced, there is Geographic Atrophy (GA) in the retina.
- Trial name
- eDREAM (NCT06659549)
- Testing
- GAL-101
- Where
- 24 sites in United States, Armenia and 6 more
- Volunteers
- 110 people
- Sponsor
- Galimedix Therapeutics Inc
Colorectal Cancer
ColoSeal™ ICD System Safety and Feasibility Studies
The studies aim to evaluate the safety and feasibility of the ColoSeal Intraluminal Colonic Diversion (ICD) System in two prospective, multicenter, single-arm studies.
- Trial name
- PROTECT I (NCT06402188)
- Testing
- ColoSeal ICD Device
- Where
- 3 sites in Armenia, Georgia and 1 more
- Volunteers
- 90 people
- Sponsor
- Averto Medical, Inc.
Hepatitis C, RDT
Simplifying Hepatitis C Pathways for People Who Inject Drugs in Armenia, Georgia, and Tanzania
The goal of this non-randomised, quasi-experimental, prospective comparative trial is to trial simplified care pathways for hepatitis C testing and treatment for people who inject drugs in Armenia, Georgia, and Tanzania.
- Trial name
- CUTTS HepC (NCT06159504)
- Testing
- sofosbuvir/velpatasvir (SOF/VEL), Shortened read time of rapid diagnostic test for hepatitis C virus.
- Where
- Armenia
- Volunteers
- 3,040 people
- Sponsor
- Médecins du Monde
Drug Use, Hepatitis
Low Dead-space Injecting Equipment Distribution Program for People Who Inject Drugs in Low- and Middle-income Countries
Implementation and evaluation of a distribution program for low dead-space syringes/needles (LDSS/N) in Armenia, Georgia, and Tanzania, Egypt, Nigeria, Vietnam, India, Ukraine, and South Africa.
- Conditions
- Drug Use, Hepatitis, Hiv
- Trial name
- NCT06395129
- Testing
- Low dead-space syringes/needles, Hepatitis C Antibody Rapid Diagnostic Test, HIV rapid Diagnostic Test
- Where
- 9 sites in Armenia, Georgia and 1 more
- Volunteers
- 2,400 people, healthy volunteers welcome
- Sponsor
- Médecins du Monde
Thyroid Diseases, Congenital Hypothyroidism
Prospective Evaluation of OptiThyDose
The aim of this multicentric, randomised, two-arms and single-blinded clinical trial is to prospectively evaluate OptiThyDose for Congenital hypothyroidism (CH) and Graves' disease (GD).
- Conditions
- Thyroid Diseases, Congenital Hypothyroidism, Graves Disease
- Trial name
- NCT06864351
- Testing
- OptiThyDose
- Where
- 7 sites in Armenia, France and 1 more
- Volunteers
- 150 people
- Sponsor
- University Children's Hospital Basel
Multiple Sclerosis, Relapsing-Remitting
Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-2)
- Trial name
- ENSURE-2 (NCT05201638)
- Testing
- IMU-838 tablets
- Where
- 101 sites in United States, Armenia and 12 more
- Volunteers
- 1,100 people
- Sponsor
- Immunic AG
Acute Hereditary Angio Edema
Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks
Prospective, multicenter, randomized, double-blind, parallel group, placebo- controlled, efficacy and safety phase 3 study of an intravenous human plasma- derived C1 esterase inhibitor (C1-INH) concentrate in participants with…
- Trial name
- NCT06361537
- Testing
- OCTA-C1-INH
- Where
- 25 sites in United States, Albania and 11 more
- Volunteers
- 124 people
- Sponsor
- Octapharma
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
CAYA Cancer Retrospective Cohort Study
Despite advances in cancer treatment, significant disparities in outcomes persist between high-income countries (HICs) and low-and middle-income countries (LMICs).
- Conditions
- Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Young Adult Cancer, Adolescent Cancer
- Trial name
- NCT07246213
- Testing
- Retrospective Medical Record Review
- Where
- 7 sites in Armenia, Egypt and 4 more
- Volunteers
- 18,000 people
- Sponsor
- Resonance, Inc.
Cancer, Pediatric Cancer
CAYA Cancer Prospective Cohort Study
Cancer is a leading cause of illness and death among children, adolescents, and young adults(CAYAs), especially in low- and middle-income countries(LMICs), where access to timely diagnosis and treatment is often limited.
- Conditions
- Cancer, Pediatric Cancer, Lymphoblastic Lymphoma (LBL), Acute Lymphoblastic Leukemia (ALL)
- Trial name
- NCT07632014
- Where
- 6 sites in Armenia, Egypt and 3 more
- Volunteers
- 6,000 people
- Sponsor
- Resonance, Inc.
Congenital Antithrombin Deficiency
Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery
The goal of this study is to assess the incidence of the composite of thrombotic events (TEs) and thromboembolic events (TEEs) in patients with congenital antithrombin deficiency under when they receive Atenativ for surgical…
- Trial name
- NCT04918173
- Testing
- Atenativ
- Where
- 30 sites in United States, Armenia and 12 more
- Volunteers
- 38 people
- Sponsor
- Octapharma
Cardiogenic Shock
Randomized Evaluation of Istaroxime for Stabilization in Acute Heart Failure-Cardiogenic Shock
The goal of this clinical trial is to learn if the drug istaroxime works to treat cardiogenic shock due to acute heart failure in adults. It will also learn about the safety of istaroxime.
- Trial name
- RESCUE HF-CS (NCT07583446)
- Testing
- istaroxime
- Where
- Armenia
- Volunteers
- 600 people
- Sponsor
- Seismic Pharmaceuticals Operations LLC
Shock, Cardiogenic
A Phase 1b/2a Trial to Evaluate Invobenitug Also Known as Procizumab (PCZ; AK1967) in Critical Cardiovascular Care.
The objective of this Phase 1b/2a trial is to evaluate the safety, tolerability, and exploratory efficacy of invobenitug (also known as procizumab), a monoclonal antibody under development for the treatment of cardiogenic shock…
- Trial name
- PROCARD 2a (NCT06832722)
- Testing
- AK1967 (Invobenitug also known as Procizumab)
- Where
- 37 sites in Armenia, Belgium and 7 more
- Volunteers
- 90 people
- Sponsor
- 4TEEN4 Pharmaceuticals GmbH
Non Squamous Non Small Cell Lung Cancer
A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)
This is a randomized, multicenter, multinational, double-blind, integrated pharmacokinetics (PK) and efficacy similarity study to compare the PK, efficacy, safety, and immunogenicity of MB12 versus Keytruda® in combination with…
- Trial name
- NCT06687369
- Testing
- MB12 (Proposed Pembrolizumab Biosimilar), EU-sourced Keytruda®, US-sourced Keytruda®
- Where
- 173 sites in Armenia, Bosnia and Herzegovina and 22 more
- Volunteers
- 726 people
- Sponsor
- mAbxience Research S.L.
Heart Failure
Snapshot Study on Patients With Heart Failure
The goal of this observational study is to provide a better understanding of medical practice for heart failure management based on real-world data, collected both across Europe and the rest of the world, using robust methodology…
- Trial name
- GRASP-HF (NCT06469814)
- Where
- 63 sites in Armenia, Austria and 9 more
- Volunteers
- 4,000 people
- Sponsor
- European Society of Cardiology
Cholangiocarcinoma
An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma
A Phase 3b research study to consolidate the data that ivosidenib is safe and effective in adult patients with previously treated, locally advanced, or metastatic cholangiocarcinoma (CCA).
- Trial name
- ProvIDHe (NCT05876754)
- Testing
- Ivosidenib Oral Tablet
- Where
- 84 sites in Armenia, Australia and 14 more
- Volunteers
- 299 people
- Sponsor
- Servier Affaires Médicales
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
Extension study to provide ongoing long-term treatment with ASTX727 for participants who were benefitting from ASTX727 treatment in a previous Taiho (formerly Astex)-sponsored clinical study of ASTX727 (including, but not limited…
- Conditions
- Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT04093570
- Testing
- ASTX727
- Where
- 47 sites in United States, Armenia and 11 more
- Volunteers
- 332 people
- Sponsor
- Taiho Oncology, Inc.
Opioid-Induced Constipation (OIC)
Safety and Pharmacokinetics Study of Naldemedine in Paediatric Participants Receiving Opioids
The primary objective of this study is to evaluate the pharmacokinetic (PK) profile of naldemedine and nor-naldemedine after a single oral dose of naldemedine in pediatric participants who are receiving or about to receive…
- Trial name
- NCT05588323
- Testing
- Naldemedine
- Where
- 16 sites in Albania, Armenia and 6 more
- Volunteers
- 24 people
- Sponsor
- Shionogi
Myelofibrosis
Clinical Epidemiology in Contemporary Patients With Myelofibrosis.
Multicenter retrospective and prospective European observational study. At each site, all consecutive patients with a 2016- or 2022 World Health Organization (WHO) confirmed diagnosis of myelofibrosis (MF) established from…
- Trial name
- ERNEST-3 (NCT06533813)
- Where
- 27 sites in Armenia, Germany and 4 more
- Volunteers
- 617 people
- Sponsor
- FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)
TX000045-003 is a double-blind, randomized, parallel group, placebo-controlled, proof- of-concept (POC) study, evaluating 2 dose regimens of TX000045 over the course of a 24-week treatment period (the APEX study).
- Trial name
- NCT06616974
- Testing
- TX000045- Dose A, TX000045- Dose B
- Where
- 72 sites in United States, Armenia and 15 more
- Volunteers
- 191 people
- Sponsor
- Tectonic Therapeutic
Nodal Marginal Zone Lymphoma
Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma
International retrospective observational cohort study aimed to describe a molecular classification for NMZL.
- Trial name
- NCT05700149
- Where
- 50 sites in United States, Argentina and 13 more
- Volunteers
- 300 people
- Sponsor
- International Extranodal Lymphoma Study Group (IELSG)